|Country||Agency||Year work was carried out||Link||Details of use|
|Austria||GOeG||2018||-||Dissemination to decision-makers.|
|Austria||HVB||2018||LINK||National adaptation. Made minor changes to information used. Added budget impact or cost effectiveness analysis.|
|Croatia||AAZ||2018||LINK||National adaptation. Carried out translation. Added local information|
|Denmark||Danish Medicines Council||2018||LINK||Cited in report as background information.|
|Italy||ASSR RER||2018||Dissemination through our website: alert of publication and link to document; summary and results reported on news page|
|Italy||UCSC||2018||National adaptation. Added local information.|
|Hungary||NIPN||2018||Used to justify our findings in the Technology Appraisal Committee meeting|
|Norway||NOMA||2018||LINK||National adaptation. Added local information.|
|Portugal||INFARMED||2018||National adaptation. Translated report. Added local information.|
|Slovakia||UNIBA||2018||National adaptation. Added local information.|
|Spain||AEMPS||2018||LINK||Cited in report as background or additional information.|
|Spain||OSTEBA||2018||LINK||PTJA03 assessment disseminated to oncologists and relevant decision makers (managers of the Pharmacy section of the Basque Health Service).|
|Spain||AETSA||2018||LINK||National adaptation. No changes to the information. Translated into Spanish.
A summary of this assessment in Spanish together with the full English report has been published on AETSA's website for dissemination. In addition, the report has been distributed to regional decision-makers and oncologists.
|Sweden||TLV||2018||LINK||National adaptation. Added local information.|
|UK (England)||NICE||2018||LINK||Read the assessment for background information. Used the assessment to inform the evaluation or consideration of a company submission of evidence.|
|UK (Scotland)||SMC||2018||LINK||Used the assessment to inform the evaluation or consideration of a company submission of evidence. Updated evidence.|
|Finland||HILA||2018||Read the report for background information. Were unable to fully utilize the report due to a different comparator. HILA also have to present our assessments in Finnish and in a specific structure.|
|Austria||LBI-HTA||2018||LINK||1:1 in LBI-HTA Horison Scanning in Oncology-programme.
|Ireland||NCPE||2018-2019||-||Read the assessment for background information.|
|Poland||AOTMiT||2018-2019||-||National adaptation. Added local information.|
|Czech Republic||SUKL||2019||-||Used as background information.|